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The influence of cellulose ether derivatives on ibuprofen
release from matrix tablets was investigated. Raman spectros-
copy and differential scanning calorimetry (DSC) experiments
were used, in order to examine the compatibility between the
matrix components: both excipients and ibuprofen. While both
the DSC and Raman results did not detect any incompatibilities,
DSC revealed the existence of some drug:excipient interactions,
reflected by variations in the hydration/dehydration processes.
Formulations containing mixtures of polymers with both low and
high viscosity grades—methylcellulose (MC25) or hydroxypro-
pylcellulose (HPC), and hydroxypropylmethylcellulose (HPMC
K100M), respectively—were prepared by a direct compression
method (using 20, 25, and 30% of either MC25 or HPC). The
tablets were evaluated for their drug content, weight uniformity,
hardness, thickness, tensile strength, friability, porosity, surface
area, and volume. Parameters such as the mean dissolution time
(MDT) and the dissolution efficiency (DE) were calculated in all
cases. The solid formulations presently studied demonstrated a
predominantly Fickian diffusion release mechanism.
Keywords ibuprofen, cellulose ether polymers, polymer mixture,
drug release, matrix tablets, release mechanism
INTRODUCTION
Ibuprofen is a well known nonsteroidal anti-inflammatory
drug (NSAID), which was the first phenylalkanoic acid
approved by the United States Food and Drug Administra-
tion (FDA) for general analgesic use. Its mode of action,
while similar to that of other nonsteroidal anti-inflammatory
agents, is not yet completely understood, but may be related
to prostaglandin synthesis inhibition. Ibuprofen, which is
available in 200, 400, 600, and 800 mg tablets for oral
administration, is rapidly absorbed when conventional
formulations are used and its peak serum concentration is
generally attained 1–2 hours after administration.[1]
The most frequent adverse effects associated with
ibuprofen include peptic ulceration and gastrointestinal
disturbances (e.g., bleeding).[1] Therefore, the quest for a
controlled release dosage form of this drug seems to be
one rational approach in order to achieve a reduction of
adverse effects of drug administration, a lower plasma
peak, and an improvement of patient compliance.[2,3]
Numerous polymers can be used for the preparation
of oral controlled release dosage forms, in view of modu-
lating the kinetic drug release process.[4] Cellulose deriva-
tives, for instance, have been successfully used with this
objective.[5,6] The choice of the polymer viscosity grade is
of the utmost importance, as the drug release mechanism
can be altered by combining different polymers with dis-
tinct viscosity grades.[7] In fact, these polymer mixtures
have been used more and more in the last few years.[8–13]
On the other hand, previous studies developed by Vueba
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et al.,[14,15] dealing with drug release from tablets contain-
ing polymers such as methylcellulose (MC25) and hydrox-
ypropylcellulose (HPC), demonstrated that formulations
using a low viscosity grade exhibited an undesired greater
erosion and faster release of the drug. Consequently, poly-
mer mixtures comprising both low viscosity and high vis-
cosity components seem to be advantageous for obtaining
appropriate modified release systems.
Several mathematical models (zero-order, first-order,
Higuchi, and Korsmeyer-Peppas) lately have been tested, in
an attempt to understand the drug release mechanism from
hydrophilic matrices. Baveja et al.[16] and Vázquez et al.[17]
verified that one of the drawbacks of the mixtures contain-
ing hydrophilic swellable polymers is that the desirable
zero-order kinetics are not usually attained. On the other
hand, Bettini et al.[18] using different cellulose ether deriva-
tives, reported that matrix tablets prepared with low viscos-
ity grade HPMC were more erodible. Moreover, according
to Rodriguez et al.[19] the drug release profiles can be modi-
fied by optimizing the erosion rate.
The present study is focused on the use of cellulose
ether polymer mixtures in ibuprofen formulations: either
methylcellulose (MC25) or hydroxypropylcellulose
(HPC), with hydroxypropylmethylcellulose (HPMC
K100M). The influence of the diluent—lactose monohy-
drate (LAC) or β-cyclodextrin (β-CD)—is also consid-
ered. In the near future, studies on mixtures comprising
MC25 or HPC, with HPMC K15M will be described.
Hopefully, this will contribute to an elucidation of the role
of the most commonly used cellulose ethers on ibuprofen
release or similar drugs from matrix tablets.
MATERIALS AND METHODS
Chemicals
Ibuprofen (IBP) (Lot no. 9907257) was purchased from
Knoll, Nottingham, England and used as a model drug.
Flurbiprofen (FNP) (Lot No 91K3452) was supplied by
Sigma-Aldrich, Chemie Gmbh, Steinheim, Germany and
employed as an internal standard. Three different viscosity
grades of cellulose ether polymers were used in the formula-
tions (Table 1). Diluents included lactose monohydrate
(LAC) (Granulac® 200, Meggle, Wasserburg, Germany) and
β-cyclodextrin (β-CD) (Kleptose®, Roquette, Lestrem,
France). Lubricants were talc and magnesium stearate (Mg S),
of analytical grade. Indium (99.98%) was obtained from Ald-
rich®, Milwaukee, USA. Acetonitrile (ACN) and methanol
were HPLC grade purchased from Merck KgaA, Darmstadt,
Germany. Water was obtained by a Millipore Elix system.
Raman Spectroscopy
The Raman spectra were obtained on a triple mono-
chromator Jobin-Yvon T64000 Raman system (focal dis-
tance 0.640 m, aperture f/7.5) equipped with holographic
gratings of 1800 grooves.mm−1. The premonochromator
stage was used in the subtractive mode. The detection sys-
tem was a liquid nitrogen cooled, nonintensified 578 × 385
pixel (1/2") Charge Coupled Device (CCD). A Coherent
(model Innova 300–05) Ar+ laser was used as the light
source, the output of which, at 514.5 nm, was adjusted to
provide 35 mW at the sample position. A 90° geometry
between the incident radiation and the collecting system
was employed. The entrance slit was set to 200 μm, and
the slit between the premonochromator and the spec-
trograph was opened to 12 mm. An integration time of 3 s
and 10–15 scans were used in all experiments.
Samples were sealed in Kimax glass capillary tubes of
0.8 mm inner diameter. Under the previously mentioned
conditions, the error in wavenumbers was estimated to be
within 1 cm−1.
Differential Scanning Calorimetry (DSC)
Thermal analysis was carried out using a Shimadzu
DSC-50 calorimeter, coupled to a Shimadzu TA-50 analyzer.
The samples were heated in sealed aluminium pans under a
nitrogen flow (20 mL/min). 3 mg of either pure drug or pure
Table 1 
Cellulose ether polymers gradesa
Polymer Methoxyl % Hydroxypropoxyl % Viscosity (mPa.s)b Brand® Lot number
MC25 27.5–32 0 10–25 Methocel A MFCD00081763
HPC 0 53.4–77.5 1500–3000c Klucel HF 8174
HPMC K100M 19–24 7–12 16922–19267 Methocel K 100M OB12012N11
aAccording to the supplier.
bApparent viscosity, 2% aqueous solution at 20°C, mPa.s according to the supplier.
cApparent viscosity, 1% aqueous solution at 20°C, mPa.s according to the supplier.
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polymer, and 9 mg of the drug/polymer mixture 1:1:1 (w/w)
were analyzed, from 25 to 250°C at a heating rate of 10°C/
min. An empty sealed pan was used as a reference. The appa-
ratus was calibrated with indium (m.p. 156.65°C).
Liquid Chromatographic Analysis
Instrumentation
The HPLC consisted of a quaternary pump Hewlett
Packard (Waldbram, Germany) model 1050, equipped with
a variable wavelength Hewlett Packard 1050 detector, a
Hewlett Packard 3396A recorder/integration, and an injector
with a 20 μL loop (model 7125, Rheodyne, Cotati, U.S.A.).
Chromatographic Conditions
The following conditions were based on the proposed
method by Shah and Jung.[20] A reversed-phase column RP-
18 LiChroCart® Purospher® star (250 × 4.6 mm i.d) 5 μm
(Merck, Darmstadt, Germany) was used at room temperature
(20–23°C). The detector was set at 229 nm. Analysis were
carried out isocratically using a four component mobile
phase, ACN:water:methanol:phosphoric acid (58:37:5:0.05,
v/v). The mobile phase was filtered using a 0.45 μm mem-
brane filter PVDF, Tracer®, Teknokroma, Barcelona, Spain
(Lot no 103527) and was degassed prior to use. The injection
volume was 20 μL and the flow rate was 1.5 mL/min.
Validation Study
Stock solutions of IBP (500 μg/mL) and FNP (300 μg/
mL; internal standard) were prepared by their dissolution in
ACN. Five standard solutions corresponding to IBP (5–50
μg/mL) containing 300 μg/mL of FNP were prepared. A
20 μL volume was then injected into the chromatograph
and the calibration curve was calculated by linear regres-
sion of peak area ratios of IBP to internal standard vs. con-
centration. Unknown IBP concentrations were determined
from the following regression equation:
where Y is the peak area ratio and X is the concentration
of IBP in μg/mL. The correlation coefficient of 0.9999
proved excellent linearity.
The repeatability (intra-assay precision) and interme-
diate (interday precision) were calculated by analysis of
three standard solutions on five different days. The
relative standard deviations obtained were between
0.38%–0.71% (n = 10) and 0.16%–0.68% (n = 5) respec-
tively, demonstrating acceptable precision.
The accuracy of solutions with known IBP concentra-
tions (10, 20, 40 μg/mL) added to the correspondent
amount of excipients was analyzed. The results for recov-
ery varied between 99.17%–101.42%, which indicates
good effectiveness.
Preparation of the Matrix Tablets
Different amounts of MC25 or HPC in the mixtures
with HPMC K100M were tested: 14/56, 17.5/52.5, and 21/
49 mg (Table 2). In all cases, the drug content was kept at
200 mg, for a total tablet mass of 350 ± 2 mg. The diluent
was either LAC or β-CD. Both talc and magnesium stear-
ate were used as lubricants. The following percentage
Y X= +0 0180 0 0062. . (1)
Table 2 
Matrix tablet composition (mg)
Formulation
Component
IBP MC25 HPC HPMC K100M LAC β-CD Talc Mg.S
A1 200.0 14.0 — 56.0 71.0 — 6.0 3.0
A2 200.0 14.0 — 56.0 — 71.0 6.0 3.0
A3 200.0 17.5 — 52.5 71.0 — 6.0 3.0
A4 200.0 17.5 — 52.5 — 71.0 6.0 3.0
A5 200.0 21.0 — 49.0 71.0 — 6.0 3.0
A6 200.0 21.0 — 49.0 — 71.0 6.0 3.0
B1 200.0 — 14.0 56.0 71.0 — 6.0 3.0
B2 200.0 — 14.0 56.0 — 71.0 6.0 3.0
B3 200.0 — 17.5 52.5 71.0 — 6.0 3.0
B4 200.0 — 17.5 52.5 — 71.0 6.0 3.0
B5 200.0 — 21.0 49.0 71.0 — 6.0 3.0
B6 200.0 — 21.0 49.0 — 71.0 6.0 3.0
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compositions were thus considered: IBP, 57.14%; polymer
mixture, 20.00%; diluent, 20.29%; talc, 1.71%; magnesium
stereate, 0.86%. The tablets were prepared according to
Vueba et al.,[14] using a single punch press (Specac Press,
Automatic Press Ltd., England) at a compaction pressure of
624 MPa, with flat-faced punches of 10 mm diameter.
IBP Content
The sample solutions were prepared from each formu-
lation by grinding five randomly selected tablets to a pow-
der and transferring a weighed amount equivalent to 20 mg
of IBP of the resulting powder to ACN with stirring and
dilution to 100 mL with more solvent. An aliquot sample (1
mL) was removed, filtered through a 0.45 μm membrane
filter, and transferred to a 10 mL volumetric flask with 1 mL
of FNP (300 μg/mL), and then made to volume with ACN.
This solution (20 μL) was injected into the HPLC, under
previously described conditions, and analyzed.
Determination of the Weight, Hardness, and Thickness 
of the Tablets
A total of 20 tablets of each formulation were evaluated
for weight (analytical balance KERN 770). For each formula-
tion, a tablet breaking–strength measuring apparatus (Erweka
TBH28, Erweka GmbH, Germany) was used, in order to
determine the hardness of 10 tablets, in a diametric direction.
The thickness was determined using a micrometer (Roche,
Switzerland), for 10 individual tablets of each formulation.
Determination of the Mechanical Tensile Strength
The tensile strength (T) was determined, for 10 matrix
tablets of each formulation, from the force required to
fracture the tablets by diametral compression on a tablet
hardness tester (Erweka TBH28, Erweka GmbH, Germany),
according to the equation:
where P is the applied load, and D and t represent the
diameter and thickness of the tablet, respectively.[21]
Determination of the Friability
Twenty tablets were weighed, placed into a friability
tester (Erweka TA20, Germany), and subjected to 25 rpm
for 4 minutes and then reweighed in order to obtain the fri-
ability value. This process was repeated for all formula-
tions and the percentage friability was calculated using the
equation:
where F represents the percentage weight loss, and W1 and
W2 are the initial and final tablet weights, respectively.
Tablets Porosity Determination
The percent porosity of the tablets was calculated
using Eq. (4), according to Schreiner et al.[22]
where ε is the percent of porosity, pa is the apparent den-
sity, pt is the true density. The true density of the tablet
was measured by means of a helium pycnometer (Accu-
Pyc TM-1330, England) as the test gas. The apparent den-
sity of the tablet was calculated using the dimensions and
the mass of 10 tablets was determined with a micrometer
(Roche, Switzerland) and an analytical balance KERN
770. All measurements were performed in triplicate, for
10 tablets of each formulation.
Determination of the Surface Area
The tablet surface area (SA) was calculated using the
following equation:
where r is the radius of the 10.00 mm flat-faced round tab-
let, and t is the band thickness of the tablet.
Swelling Studies
Swelling studies were carried out for all formulations.
Three metallic baskets were weighed with a matrix tablet
of each formulation, and placed in 1000 mL of phosphate
buffer pH = 7.2 at 37.0 ± 0.5°C. At hourly intervals, the
previously weighed baskets containing the tablet were
removed, gently wiped with a tissue in order to remove
T
P
Dt
=
2
π
(2)
F
W W
W
=
−
×1 2
1
100
(3)
ε(%) = −⎛⎝⎜
⎞
⎠⎟ ×1 100
pa
pt
(4)
SA r r t= +2 π ( ) (5)
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Influence of Cellulose Ether on Ibuprofen Release 217
surface water, reweighted, and then placed back into the
vessel as quickly as possible. The mean weights were
determined for each formulation, and the degree of swell-
ing (S) was calculated according to the relationship.[23]
where Wd and Ws are the dry and swollen matrix weights,
respectively, at immersion time (t) in the buffer. The
swelling degree was the mean of three determinations.
Drug Release Analysis
Dissolution studies were carried out according to
the USP 25 paddle method.[24] Phosphate buffer was
used as the dissolution medium (pH = 7.2, 1000 mL) at
37.0 ± 0.5°C, for a stirring speed of 100 rpm. A six-vessel
dissolution apparatus (Vankel VK-7000 dissolution test-
ing station) was used for this purpose, in-line with a
closed flow through system coupled to a peristaltic
pump, connected to a spectrophotometer (Shimadzu
UV-1603). Six different tablets were tested. The progress
of the dissolution was monitored by withdrawing fil-
tered samples every 5 min, for a total of 1200 min. The
amount of IBP present in each sample was determined
spectrophotometrically at λ = 264 nm. The correspond-
ing drug-release profiles were represented by plots of
the cumulative percentage of drug release (calculated
from the total amount of IBP contained in each matrix)
vs. time.
Determination of the Mean Dissolution Time
In order to further characterize the drug release pro-
cess, the mean dissolution time (MDT) was calculated,
according to the following equation
where j is the sample number, n is the number of dissolu-
tion sample times,  is the time at midpoint between tj
and tj−1, and ΔQj is the additional amount of drug dis-
solved between tj and tj−1.
Determination of the Dissolution Efficiency
The dissolution efficiency (DE) is defined by the area
under the dissolution curve (AUC) at time, t. It is
expressed as a percentage of the area of the rectangle
corresponding to a 100% dissolution, for the same total
time, [25,26] according to the following equation:
where y is the drug percentage dissolved at time t.
Kinetic Mechanism
The kinetics of IBP release from hydrophilic cellulose
matrix tablets were determined by finding the best fit
(through minimization of the sum of the squared residuals)
of the dissolution data (released fraction vs. time) to dis-
tinct mathematical models. The models considered only
the points comprised in the interval 0.1 < Qt/Q∞ < 0.7.
The cumulative percentage of released drug vs. time
was assessed, for a zero-order model, which results in a
linear rate of drug release with time, in accordance with
the equation
where Qt is the amount of drug released at time t, Q0 is the
amount of drug in the solution at t = 0, (usually, Q0 = 0),
and k0 is the zero-order release constant.
Gibaldi and Feldman,[27] in turn, applied the follow-
ing relationship to drug dissolution studies, in order to
describe nonconstant release from reservoir devices,
where k1 represents the first-order kinetic constant.
In the early 1960s, Higuchi[28,29] developed a model
aimed at describing the release process of a drug incorpo-
rated in a solid or semisolid matrix,
where kH is the Higuchi rate constant.
Moreover, in order to better characterize the drug
release behavior, for the polymeric systems studied, the
Korsmeyer-Peppas semi-empirical model was also
applied.[30,31]
S W W
W
s d
d
=
−
× 100 (6)
MDT
Q
Q
j
j
n
j
j
n
=
=
=
∑
∑
t^ Δ
Δ
1
1
1
(7)
tˆ j
DE
y dt
y t
t
=
×
×
×
∫
0
100
100
(8)
Q Q k tt = +0 0 (9)
Q et k t= − −100 1 1( ) (10)
Q k tt H
t
=
2 (11)
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Qt/Q∞ being the fraction of drug released at time t, k a
constant comprising the structural and geometric charac-
teristics of the tablet, and n (the release exponent) a
parameter indicative of the mechanism of drug release.[32]
For the particular case of cylindrical tablets,[33] n ≤ 0.45
corresponds to a Fickian diffusion release (case I diffu-
sional), 0.45 < n < 0.89 to an anomalous (non-Fickian)
transport, n = 0.89 to a zero-order release kinetics (case II),
and n > 0.89 to a super case II transport.
Statistics
In order to assess statistical significance among the
data, one way analysis of variance (ANOVA) was used to
test variation in tablets formulations containing different
polymer mixtures, MC25/HPMC K100M or HPC/HPMC
K100M, at the different % w/w and in the same dissolu-
tion media. The ANOVA was utilized as well as to test
differences in the physical characterization of the matrix
tablets. The difference between variants was considered
significant if p < 0.05, followed by the Bonferroni com-
parison t-test. The statistical work was done using Sigma
Stat® for Windows version 2.03 software, 1992–1997
SPSS Inc.
RESULTS AND DISCUSSION
Raman Spectroscopy
The Raman spectra (in the solid state, 25°C) of the
different components of the mixtures to be studied—IBP,
polymers (MC25, HPC, and HPMC K100M) and diluents
(β-CD and LAC)—are shown in Figure 1.
The spectrum of IBP presents intense and well-
defined features, most of them directly correlatable with
specific groups within the molecule. The spectrum of each
of the polymers, in turn, display less intense and resolved
features, as well as some background fluorescence due to
their physico-chemical characteristics.
Figure 2 contains the Raman spectra of 1:1 (w/w)
IBP:excipient freshly prepared physical mixtures. Despite
the particular drug:excipient ratio used, these spectra
reflect mostly the presence of the drug. However, a closer
inspection suggests that they correspond to the superposi-
tion of the individual band patterns of IBP, and either the
polymer or the diluent.
Particularly interesting and useful to this study is the
1500–1800 cm−1 spectral region, as none of the excipi-
ents tested gives rise to vibrational bands in this interval
(Figure 1). Consequently, any change observed in the
IBP signals, tentatively assigned to both C=O and ring
stretching vibrational modes, should arise from intermo-
lecular interactions between the different components in
the physical mixture (mainly those involving the IBP
carboxylic group).
Analysis of the spectra presented in Figure 2 allows
one to conclude that neither new bands nor relative intensity
or frequency variations were observed in the mixtures.
Q Q ktt n/ ∞ = (12)
Figure 1. Raman spectra (solid state) for ibuprofen (IBP),
methylcellulose (MC25), hydroxypropylcellulose (HPC),
hydroxypropylmethylcellulose (HPMC K100M), β-cyclodextrin
(β-CD), and lactose.
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These spectroscopic results evidence the absence of sig-
nificant intermolecular interactions between IBP and the
excipients under study, in freshly prepared solid physical
mixtures.
Differential Scanning Calorimetry (DSC)
The DSC was used in order to detect formulation
incompatibilities resulting from possible drug:excipient
interactions. The thermal curves of isolated IBP and the
distinct polymers used are comprised in Figure 3a;
whereas different binary and ternary mixtures are shown
in Figures 3b and 3c. The results obtained for IBP were the
ones expected for a crystalline anhydrous substance, dis-
playing a sharp endothermic peak at 75.0 ± 0.5°C, which
corresponds to the drug´s melting point.[34]
The DSC thermograms of IBP/β-CD, IBP/LAC, and
IBP/polymer 1:1 (w/w) mixtures, were recently studied by
Vueba et al.,[15] who concluded there is an absence of
incompatibilities between these matrix components.
The results for the 1:1 and 1:3 (w/w) binary mixtures
(MC25/HPMC K100M and HPC/HPMC K100), shown in
Figures 3b and 3c were not found to differ significantly
from the DSC curves of isolated MC25, HPC, or HPMC
K100M (Figure 3a), where a large broad endothermic
effect was observed over a temperature range of 60 to
140°C, due to the dehydration process. The occurrence of
a shift to lower temperatures in these endothermic events
(Figures 3b and 3c) must be pointed out, reflecting a
straightforward dehydration in the polymer mixtures.
Regarding the ternary systems IBP/MC25/HPMC
K100M and IBP/HPC/HPMC K100M (Figures 3b and
3c), the drug signal was clearly distinguishable. Further-
more, clear downward shifts of the excipient signals, upon
dehydration, were also seen. This may be related to the
presence of nonnegligible drug:excipient interactions,
possibly responsible for a loosening of the water-polymer
binding strength, due to some degree of competition
between the drug ionizable groups (e.g., carboxylates).
These results are in accordance with the ones obtained for
IBP:polymer binary mixtures.[15]
Moreover, the broad signal observed at about 200°C in
the ternary mixtures (Figures 3b) could be attributed to either
a glass transition or to polymer degradation products.[35]
The DSC results presently described suggest the
existence of both polymer:polymer and IBP:polymer inter-
actions that modulate the hydration/dehydration processes.
Since no other endothermic events were observed, one can
state that no incompatibilities were found between IBP
and the polymers studied, whose presence could prevent
their simultaneous use in pharmaceutical formulations.
Also, since the intermolecular interactions described
earlier, mainly associated with the hydration/dehydration
mechanisms are rather weak, they are not likely to be
detected by Raman. In fact, this spectroscopic technique
does not allow observation of the water vibrational modes,
which are much more affected by the dehydration process,
but almost inactive in Raman.
Evaluation of the Tablet Properties
The drug content and physical characteristics of the
matrix tablets containing either MC25 or HPC as release
Figure 2. Raman spectra (solid state) for IBP/MC25, IBP/
HPC, IBP/HPMC K100M, IBP/β-CD, and IBP/lactose, 1:1 (w/w)
physical mixtures.
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modulators are shown in Tables 3 and 4, respectively. The
HPLC analysis in all cases yields a drug content ranging
from 99.30% to 100.45%, based on the theoretical compo-
sition, which evidences content uniformity. The differ-
ences in the mean values among the treatment groups are
not great enough to exclude the possibility that the differ-
ence is due to random sampling variability; there is not a
statistically significant difference (F = 2.34; P > 0.05).
Table 5 contains the statistical parameters correspond-
ing to the measured data—mean values, standard deviation
(SD), relative standard deviation (RSD), median, variance,
and minimum and maximum values of the IBP matrix
formulations relative to mass uniformity. The ANOVA
revealed that uniform weight of all formulations were dif-
ferent in the mean values among the treatment groups are a
little greater than would be expected by chance; there is a
Figure 3. DSC curves for IBP (A), MC25 (B), HPC (C), HPMC K100M (D); binary and ternary physical mixtures.
A:B:D
B:D
0 50 100 150 200 250
Temperature (ºC)
C:D
A:C:D
b)
Binary (1:1) and 
Ternary (1:1:1) mixtures
0 50 100 150 200 250
B:D
C:D
A:B:D
A:C:D
c)
Binary (1:3) and 
Ternary (1:1:3) mixtures
0 50 100 150 200 250
A
B
C
D
a)
Single Component
Table 3 
Physical characterization of MC25-containing IBP hydrophilic matrix tabletsa
Formulation 
code
Drug content (mg) 
n = 3
Hardness (N) 
n = 10
Thickness (mm) 
n = 10
T. strength (MPa) 
n = 10
Friability (%) 
n = 20
A1 19.86 ± 0.05 94.03 ± 1.55 3.81 ± 0.03 1.571 ± 0.027 0.70
A2 19.87 ± 0.03 86.92 ± 1.91 3.83 ± 0.01 1.446 ± 0.030 0.89
A3 19.99 ± 0.01 97.13 ± 1.66 3.80 ± 0.01 1.626 ± 0.027 0.87
A4 19.88 ± 0.02 94.53 ± 1.90 3.83 ± 0.03 1.571 ± 0.032 0.95
A5 20.05 ± 0.21 99.47 ± 1.81 3.81± 0.04 1.661 ± 0.007 0.62
A6 20.26 ± 0.02 91.62 ± 3.25 3.83 ± 0.04 1.524 ± 0.056 0.84
True density 
(g/cm3) n = 10
Apparent density 
(g/cm3)b n = 10
Porosity (%) 
n = 10
Surface area (mm2) 
n = 10
A1 1.2424 ± 0.0004 1.1652 ± 0.0018 6.21 ± 0.14 276.81 ± 0.10
A2 1.2330 ± 0.0003 1.1593 ± 0.0028 5.98 ± 0.23 277.31 ± 0.31
A3 1.2436 ± 0.0002 1.1640 ± 0.0021 6.40 ± 0.17 276.56 ± 0.21
A4 1.2365 ± 0.0004 1.1629 ± 0.0024 6.00 ± 0.19 277.43 ± 0.10
A5 1.2456 ± 0.0002 1.1638 ± 0.0030 6.57 ± 0.24 276.84 ± 0.13
A6 1.2376 ± 0.0003 1.1629 ± 0.0025 6.03 ± 0.20 277.34 ± 0.13
aMean value ± Standard Deviation.
bUsing the equation: density = weight (g)/volume (cm3).
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statistically significant difference (F = 13.59; P < 0.001).
However, when comparing formulations (A1–A6) and
(B1–B6), it was possible to detect a certain uniformity,
since the SD and RSD were lower than 1.0 mg and 0.3%,
respectively. The variance of all formulations was below
1.0%, evidencing a homogenous distribution of the drug in
the tablets. The maximum value measured for formula-
tions (A1–A6) was 350.90 mg, while the minimum value
was 347.00 mg. Like results were obtained for mixtures
(B1–B6).
The hardness values of various formulation matrices
were found to be different within the range of 50.63 N to
99.47 N (F = 2504.39; P < 0.05), which corresponds to obvi-
ous variations in the tablet tensile strength from 0.84 MPa to
1.66 MPa (F = 885.77; P < 0.001). Results also confirmed
that the porosity of the tablets is influenced by the kind of
diluent used and also has an influence on the tablet tensile
strength. Tablets with higher hardness values were found to
have higher porosity values, and therefore a decrease of the
drug release rate, in accordance with previously reported
Table 4 
Physical characterization of HPC-containing IBP hydrophilic matrix tabletsa
Formulation 
Code
Drug content (mg)
n = 3
Hardness (N) 
n = 10
Thickness (mm) 
n = 10
T. strength (MPa) 
n = 10
Friability (%)
n = 20
B1 20.14 ± 0.15 88.12 ± 1.37 3.84 ± 0.03 1.461 ± 0.023 0.86
B2 20.30 ± 0.46 54.92 ± 1.29 3.85 ± 0.03 0.908 ± 0.021 0.94
B3 20.21 ± 0.29 86.02 ± 1.63 3.83 ± 0.05 1.428 ± 0.026 0.83
B4 20.19 ± 0.01 78.32 ± 0.95 3.84 ± 0.01 1.297 ± 0.015 0.92
B5 20.24 ± 0.01 80.45 ± 1.35 3.84 ± 0.03 1.334 ± 0.023 0.54
B6 20.29 ± 0.03 50.63 ± 1.43 3.85 ± 0.03 0.838 ± 0.023 0.76
True density 
(g/cm3) n = 3
Apparent density
(g/cm3)b n = 10
Porosity (%) 
n = 10
Surface area (mm2)
n = 10
B1 1.2325 ± 0.0003 1.1546 ± 0.0018 6.11 ± 0.66 277.75 ± 0.10
B2 1.2244 ± 0.0001 1.1529 ± 0.0016 5.83 ± 0.13 278.00 ± 0.10
B3 1.2322 ± 0.0001 1.1572 ± 0.0026 6.09 ± 0.21 277.53 ± 0.16
B4 1.2285 ± 0.0003 1.1566 ± 0.0035 5.85 ± 0.29 277.84 ± 0.26
B5 1.2323 ± 0.0001 1.1576 ± 0.0040 6.06 ± 0.33 277.69 ± 0.10
B6 1.2260 ± 0.0001 1.1569 ± 0.0020 5.75 ± 0.16 277.87 ± 0.50
aMean value ± Standard Deviation.
bUsing the equation: density = weight (g)/volume (cm3).
Table 5 
Statistical parameters for the IBP matrix tablets (n = 20)
Formulation Average (mg) SDa RSDb (%) Median (mg) Variance Minimum (mg) Maximum (mg)
A1 348.44 0.64 0.18 348.35 0.41 347.30 349.60
A2 348.14 0.75 0.21 348.20 0.56 347.00 349.20
A3 349.84 0.60 0.17 349.80 0.36 348.70 350.80
A4 349.83 0.90 0.26 350.00 0.81 348.20 350.90
A5 348.45 0.79 0.23 348.40 0.63 347.30 350.90
A6 349.75 0.95 0.27 350.10 0.91 348.10 350.90
B1 348.59 0.62 0.18 348.60 0.39 347.10 349.60
B2 348.76 0.75 0.21 348.90 0.56 347.20 350.50
B3 348.44 0.74 0.21 348.45 0.55 347.10 349.50
B4 349.31 0.62 0.18 349.25 0.39 348.20 350.90
B5 348.78 0.89 0.26 348.75 0.80 347.20 350.50
B6 349.40 0.79 0.22 349.30 0.62 348.00 350.80
aStandard variation.
bRelative standard variation.
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work.[15] It was also verified that the tablets passed the friabil-
ity test (F < 1%), showing that all formulations lie within the
established limits.[24] These results corroborate that a com-
paction pressure of 624 MPa could provide tablets that are
not easy broken during transportation or handling.
Hydrophilic matrix tablets manufactured with faced
punches of 10 mm diameter and equal compaction pressure
present surface area values (SAs) differing only by 0.87 mm2
and 0.47 mm2, for MC25- and HPC-containing formulations,
respectively (Tables 3 and 4). As the drug release rate is
supposed to be directly proportional to the ratio between SA
and the volume of the matrix (SA/Vol),[36] the very small
fluctuations in the SAs (<0.3%) presently measured are not
expected to have any influence on the drug release process.
Swelling Studies
An important stage for the development of a con-
trolled-release solid dosage form is the selection of an
appropriate polymer or polymer mixture, based on the
disintegration mechanism and/or on the penetration degree
of a liquid into the tablets (i.e., the polymer’s ability to
absorb water and swell). For this purpose, hydrophilic
polymers of a high viscosity grade, such as HPMC
K100M, are often chosen for their capacity to promptly
hydrate and gelatinize. Moreover, for the high molecular
weight grade of HPMC, the wetting and water uptake into
the matrices are enhanced[37,38]; although, there is also a
decrease of the drug release rate. Thus, in order to balance
these effects, while still obtaining good water uptake pro-
files, the formulations presently studied comprise HPMC
K100M mixed with lower viscosity grade polymers
(MC25 or HPC).
Figure 4 summarizes the results obtained from the
swelling experiments. All formulations were found to
attain a high degree of hydration after the first hour, essen-
tial for allowing gel layer formation prior to dissolution of
the tablet. A gradual decrease of the hydration was
observed in the following 7 hours. This decrease was even
Figure 4. Graphical representation of the water uptake vs. time for several IBP matrix formulations containing either lactose (left)
or β-cyclodextrin (right) and MC25 (top) or HPC (bottom). 
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more pronounced when either the MC25 or HPC percent-
age in the polymer is higher than 25%—in Fig. 4; the
curves corresponding to A5, A6, B5, and B6 display
higher negative gradients than the others. The time depen-
dence of the water uptake process when HPMC K100M is
mixed with either MC25 or HPC is remarkable. In fact, a
steady level was attained after 1 hour of water exposure
when HPMC K100M is the hydrophilic polymer present in
the matrices.[15]
In a previously reported study,[15] it was verified that
the absence of hydroxypropoxyl groups in the MC25
polymer, or a low hydroxyl group content, renders this
polymer less hydrophilic[39,40] and contributes to an
acceleration of the matrix disintegration process, despite
the polymer wettability increase, which may be due to gel
formation. For HPC, in turn, a low hydration level, even
for long water exposures, was found.[15]
The results obtained in this work demonstrated that
the swelling behavior of HPMC K100M in matrix tablets
is very similar to that of the mixtures of 20% of either
MC25 or HPC (i.e., formulations A1, B1, A2, B2),
Figure 4. Above this percentage, increasing differences
were observed up to a critical value of about 25%, above
which the matrix swelling performance drastically
changes, Figure 4.
Once the swelling process plays an essential role on
the drug release mechanism, a careful choice of the chem-
ical characteristics (e.g., the hydroxyl group content), the
viscosity and the relative amount of hydrophilic poly-
mers used in the matrix preparation, become of utmost
importance.
Release Studies
The dissolution profiles of different types of formula-
tions in simulated intestinal fluid (pH 7.2)—in vitro exper-
iments—are presented in Figures 5 and 6. The different
relative ratios of MC25, HPC, and HPMC K100M in the
MC25/HPMC K100M or HPC/HPMC K100M mixtures
were found to significantly affect the profiles of IBP
release. The drug release from the tablets is a result of the
hydration of the polymer mixture, which swells exten-
sively forming a pathway through which the drug can dif-
fuse. However, a gradual disintegration of the swollen
tablets is observed during the release studies, due to the
presence of low viscosity grade polymers in the mixture.
The percentage of drug released at 20 hours from A1, A2,
B1, and B2 matrices was determined to be up to 76%–
84%. For formulations A3, A4, B3, and B4 (MC25 or
HPC equal to 25%), an IBP release between 83% to 93%
was obtained. In turn, when HPMC K100M is reduced to
70%, coupled with a corresponding increase of the low
viscosity polymers (tablets A5, A6, B5, and B6), the
amount of drug released appears to be even larger than that
yielded by the former mixtures, reaching values of almost
94%–98%.
These assays, combined with previous ones per-
formed on single polymer formulations,[15] clearly show
that the incorporation of either MC25 or HPC plays an
important role as a release modifier from HPMC-contain-
ing tablets.
The β-CD-containing tablets were found to release
IBP slightly faster than the ones having lactose as a
filler. In fact, the fraction of the drug released from all
β-CD formulations (A2, A4, and A6, or B2, B4, and
B6) is found to be higher than for those containing the
analogous lactose-containing formulations (A1, A3,
and A5 or B1, B3, and B5). This observation was
supported by the smaller MDT values calculated for
β-CD formulations (Table 6 and Figure 7). Indeed, this
parameter yields information on both the drug release
process and the retarding efficacy of the polymer;
larger MDT values indicating a higher drug retarding
ability of the polymer (F = 1713.55; P < 0.001).
Figure 5. Drug-release profiles for IBP from MC25-containing
formulations. 
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Table 6 also comprises several other parameters
widely used for characterizing this kind of dissolution
processes: t50%, AUC, DE, and percentage of drug
dissolved at 20 hours (P20h), whose variations were the
ones to be expected.
Figure 7 provides a comparison of the MDT depen-
dence on the polymer ratio composition: an increase of the
low viscosity polymer MC25 content is accompanied by a
decrease in the MDT values. The same occurs for the
HPC-containing formulations (Table 6).
Kinetics of the Drug Release Mechanism
Either diffusion or erosion processes can contribute to
the drug release process from solid matrix tablets. In fact,
the release from swellable matrix systems is complex and
not completely understood, as both mechanisms are some-
times present. In such cases, it is important to select a suit-
able mathematical model, which can be adjusted to the
release profiles. The interpretation of the Korsmeyer-
Peppas exponent values (n), in particular, provides an
insight into the balance between the different mechanisms
present.
The profiles of IBP release (for 10% to 70% of
released drug) were fitted, and the results are summa-
rized in (Tables 7 and 8). The reported values suggest
that for this duration of the in vitro studies diffusion
was the predominant process, for both the MC25 and
HPC-containing formulations—exponent values (n)
ranging between 0.235 to 0.359 (Table 7), and 0.295 to
0.360 (Table 8), respectively. This is corroborated by
the good fitting obtained using Higuchi´s model. More-
over, the n and K values were found to be inversely
related. In fact, when either MC25 or HPC matrix con-
tent was increased in the formulations, the release was
markedly faster and higher values of K were obtained,
Figure 6. Drug-release profiles for IBP from HPC-containing
formulations. 
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Table 6 
Dissolution parameters for the IBP matrix tabletsa
Assay MDT (h) t50% (h) AUC DE (%) P20h (%)b
A1 5.29 ± 0.02 5.73 1132.03 56.60 ± 1.67 76.31 ± 2.14
A2 4.79 ± 0.06 5.58 1162.59 58.13 ± 1.48 83.73 ± 1.97
A3 3.46 ± 0.12 4.17 1235.13 61.76 ± 1.67 83.34 ± 3.13
A4 2.71 ± 0.13 3.07 1360.23 68.01 ± 1.32 91.64 ± 3.44
A5 1.91 ± 0.01 1.67 1475.79 73.79 ± 2.16 94.97 ± 2.76
A6 1.73 ± 0.01 1.53 1509.83 75.49 ± 1.79 97.16 ± 2.09
B1 4.95 ± 0.15 5.59 1150.71 57.54 ± 0.33 80.73 ± 1.30
B2 4.24 ± 0.10 4.86 1217.33 60.87 ± 1.03 84.56 ± 1.10
B3 2.90 ± 0.09 2.96 1378.09 68.90 ± 1.71 90.84 ± 2.11
B4 2.53 ± 0.01 2.81 1422.06 71.10 ± 1.27 93.79 ± 0.49
B5 1.81 ± 0.01 1.80 1581.90 79.09 ± 1.64 96.41 ± 1.03
B6 1.66 ± 0.01 1.81 1585.26 79.26 ± 1.78 98.84 ± 1.15
aMean ± standard variation (6 measurements).
bP20 = percentage of IBP dissolved at 20 hours.
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suggesting that a small burst effect may be present. For
all the formulations tested, the drug release rates were
found to be higher than for those containing only
HPMC K100M.[15] Given that several authors[15,41,42]
have verified that the use of different HPMC viscosity
grades (K4M, K15M, or K100M) for a given drug:
HPMC ratio, it is not enough to alter the Higuchi-type
kinetics significantly, the results obtained for both
MC25 and HPC may be explained in the light of their
particular chemical structure.
Thus, it is suggested that the use of polymer mix-
tures—using different viscosity grade polymers in order to
obtain the appropriate gels—is a promising procedure for
achieving optimal release properties.
CONCLUSIONS
The results obtained in the present study illustrate
that both low and high viscosity grade cellulose ether
polymers can be mixed uniformly, in different propor-
tions, in order to produce matrices with modulated
drug release properties. Powder mixtures compressed
at a compaction pressure of 624 MPa were verified to
provide suitable tablets that would not easily break
during transportation or handling. The studied formula-
tions, mainly A6, B5, and B6, suggest acceptable
sustained-release performance based on the in vitro
data.
While both the DSC and Raman spectroscopy
experiments did not detect any incompatibilities
between the IBP and the excipients under study, DSC
revealed the existence of some drug:excipient interac-
tions, reflected in changes in the hydration/dehydration
processes.
The swelling experiments showed that the water
uptake increases until the low viscosity polymer content
reaches 25%. At higher concentrations, the swelling
behavior changes drastically, suggesting a gradual degra-
dation of the matrices.
The dissolution of IBP from mixtures of MC25/
HPMC K100M or HPC/HPMC K100 matrices was found
to be more effective when either the MC25 or HPC con-
tent was increased.
The solid formulations studied were far from
yielding the desirable zero order kinetics, although,
they allow a predominantly Fickian diffusion release
mechanism.
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Figure 7. Graphical representation of MDT values for MC25
(top) and HPC (bottom) containing formulations.
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Table 7 
Fitting results of the IBP release data for several MC25-containing formulations (see Table 2)a
Formulation
Zero Order First Order Higuchi Korsmeyer–Peppas
K0 
(% h−1) R2
K1 
(h−1) R2
KH 
(% h−1/2) R2
KKP 
(h−n) n R
2
A1 2.839 
(0.061)
0.9523 
(0.0017)
0.040 
(0.001)
0.9792 
(0.0012)
14.314 
 (0.294)
0.9949
(0.0006)
27.151 
 (0.997)
0.342 
(0.004)
0.9895 
(0.0016)
A2 3.188 
(0.092)
0.9581 
(0.0009)
0.044 
(0.002)
0.9812 
(0.0006)
15.251 
 (0.449)
0.9988
(0.0001)
26.493 
 (0.999)
0.359 
(0.009)
0.9954 
(0.0009)
A3 3.364 
(0.125)
0.9417 
(0.0067)
0.045 
(0.002)
0.9637 
(0.0063)
14.926 
 (0.535)
0.9913
(0.0026)
32.147 
 (1.300)
0.302 
(0.014)
0.9909 
(0.0008)
A4 4.293 
(0.147)
0.9334 
(0.0085)
0.057 
(0.003)
0.9544 
(0.0080)
16.628 
 (0.554)
0.9861
 (0.0039)
35.954 
 (1.323)
0.289 
(0.013)
0.9888 
(0.0014)
A5 5.469 
(0.173)
0.8985 
(0.0006)
0.070 
(0.003)
0.9235 
(0.0012)
17.752 
(0.559)
0.9765
(0.0003)
44.167 
 (1.650)
0.236 
(0.001)
0.9945
(0.0003)
A6 5.630 
(0.256)
0.8965 
(0.0017)
0.073 
(0.003)
0.9212 
(0.0011)
18.248 
 (0.506)
0.9753
(0.0003)
45.547 
(1.304)
0.235 
(0.001)
0.9948 
(0.0004)
aValues in parenthesis mean standard deviation; R2 is the coefficient of determination; best results in bold.
Table 8 
Fitting results of the IBP release data for several HPC-containing formulations (see Table 2)a
Formulation
Zero Order First Order Higuchi Korsmeyer–Peppas
K0 
(% h−1)
R2 K1 
(h−1)
R2 KH 
(% h−1/2)
R2 KKP 
(h−n)
n R2
B1 3.103 
(0.097)
0.9552 
(0.0065)
0.043 
(0.002)
0.9785 
(0.0051)
15.020 
 (0.433)
0.9983
(0.0012)
27.043 
 (1.160)
0.351 
(0.016)
0.9973
(0.0003)
B2 3.674 
(0.040)
0.9655
(0.0030)
0.051 
(0.001)
0.9861 
(0.0015)
16.320 
 (0.195)
0.9984
(0.0004)
27.757 
 (0.967)
0.360 
(0.008)
0.9923 
(0.0007)
B3 4.654 
(0.222)
0.9538 
(0.0062)
0.062 
(0.004)
0.9740 
(0.0056)
17.612 
 (0.807)
0.9966
(0.0013)
35.411 
 (2.144)
0.305 
(0.0023)
0.9926 
(0.0013)
B4 5.460 
(0.118)
0.9547 
(0.0005)
0.074 
(0.002)
0.9740 
(0.0005)
19.365 
 (0.417)
0.9944
(0.0002)
35.457 
 (0.835)
0.322 
(0.001)
0.9911 
(0.0004)
B5 8.136 
(0.471)
0.9633 
(0.0026)
0.109 
(0.009)
0.9800 
(0.0028)
23.299 
 (1.334)
0.9949
(0.0004)
40.606 
 (1.643)
0.316 
(0.013)
0.9881 
(0.0007)
B6 7.306 
(0.270)
0.9273 
(0.0035)
0.098 
(0.005)
0.9516 
(0.0029)
22.055 
 (0.811)
0.9864
(0.0006)
41.797 
 (0.941)
0.295 
(0.007)
0.9932 
(0.0010)
aValues in parenthesis mean standard deviation; R2 is the coefficient of determination; best results in bold.
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